LLLaurence Lagarce

Laurence Lagarce

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laurence Lagarce has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Marie Briet

    Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 49100 Angers, France; Angers University, 49035 Angers, France; Research Institute MitoVasc, UMR CNRS 6214 Inserm 1083, 49100 Angers, France

    4 shared publications
  • Pascale Lainé-Cessac

    Service de pharmacologie et toxicologie, centre régional de pharmacovigilance, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France

    3 shared publications
  • Anne-Sophie Garnier

    Service de Néphrologie-Dialyse-Transplantation, Centre Hospitalo-Universitaire d’Angers, Université Angers, Angers, France

    2 shared publications
  • Bertrand Diquet

    2 shared publications
  • Chadi Abbara

    Service de Pharmacologie-Toxicologie Et Pharmacovigilance, Centre Hospitalo-Universitaire D’Angers, Angers, France

    2 shared publications
  • Delphine Bourneau-Martin

    Service de pharmacologie-toxicologie et centre régional de pharmacovigilance, CHU Angers, 49100 Angers, France

    2 shared publications

Latest Publications

  • Open Access

    Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database

    by Morgane Cellier, Delphine Bourneau-Martin, Chadi Abbara, Alexandre Crosnier, Laurence Lagarce, Anne-Sophie Garnier, Marie Briet

    Background: Alongside their BCR-ABL specificity, TKIs used in chronic myeloid leukemia also target other tyrosine kinases expressed in the kidney such as PDGFR, c-KIT, SRC, and VEGFR, which may result in specific renal adverse drug reaction (ADR). To evaluate the renal safety profile in real-life conditions, a case/non-case study was performed on VigiBase®, the WHO global safety database. Methods: From 7 November 2001 to 2 June 2021, all cases in which the involvement of imatinib, dasatinib, nilotinib, bosutinib, and ponatinib was suspected in the occurrence of renal ADR were extracted from VigiBase®. Disproportionality analyses were assessed using the reporting odds ratio. Results: A total of 1409 cases were included. Imatinib accounts for half of the reported cases. A signal of disproportionate reporting (SDR) of renal failure and fluid retention was found for the five TKIs. Only dasatinib and nilotinib were related to an SDR for nephrotic syndrome. Nilotinib and ponatinib were related to an SDR for renal artery stenosis, while dasatinib was related to an SDR for thrombotic microangiopathy. No SDR for tubulointerstitial nephritis was observed. Conclusion: This study identified a new safety signal, nephrotic syndrome, for nilotinib and highlights the importance of post-marketing safety surveillance.


  • Open Access

    Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT)

    by Marie‐Laure Laroche, Sophie Gautier, Elisabeth Polard, Marie‐Blanche Rabier, Laurent Chouchana, Bénédicte Lebrun‐Vignes, Jean‐Luc Faillie, Nadine Petitpain, Laurence Lagarce, Annie‐Pierre Jonville‐Bera, et al.

    Aims: In the last French study in 2007, the incidence of hospital admissions (HAs) related to adverse drug reactions (ADRs) was 3.6%. The objective was to assess the current ADR‐HA incidence in France and to describe both its characteristics and preventability.Methods: A prospective multicentre study was conducted among randomly selected French public hospital medical wards (April–July 2018). Patients admitted during a week period were included. ADR‐HA cases were collected by the French Regional Pharmacovigilance Centres network. An independent committee validated potential cases and ADR preventability.Results: ADR‐HA incidence was 8.5% (95% confidence interval [CI]: 7.6–9.4%), increasing with age (3.3% [95%CI: 1.8–5.5%] ≤16 y vs. 10.6% [95%CI: 9.3–12.0%] ≥65 y). The most common ADRs were haemorrhagic events (8.8%), haematological disorders (6.5%), acute renal failure (6.3%), fluid and electrolyte disorders (6.0%), and falls (5.2%). New drugs were involved: targeted therapies (22.8% of antineoplastics), direct oral anticoagulants (29.6% of antithrombotics) and incretin‐based drugs (20.0% of antidiabetics). ADRs were preventable in 16.1% of cases because the drugs involved had not been used in accordance with monographies, package leaflets or other therapeutic guidelines. The main situations of noncompliance addressed either dose or duration of use (27.9%), warning (23.2%), use precaution (18.6%) and inappropriate self‐medication or misuse by patients (11.6%).Conclusion: In France, ADR‐HA incidence dramatically increased over the last decade. A significant proportion was related to new pharmacological classes and considered as preventable. These findings should lead to in‐depth thought on preventive actions on at‐risk drug classes.


  • Open Access

    Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase® the WHO Global Database of Individual Case Safety Reports

    by Alexandre Crosnier, Chadi Abbara, Morgane Cellier, Laurence Lagarce, Marina Babin, Delphine Bourneau-Martin, Marie Briet

    Kidney EGFR expression together with reported cases of glomerular diseases in the context of anti-EGFR drug administration raise concerns about the renal safety profile of these drugs. This issue is addressed in a case/non-case study carried out on VigiBase®, the WHO global database of individual case safety reports (ICRS). Disproportionality analysis of renal adverse effects related to the selected anti-EGFR drugs, erlotinib, gefitinib, afatinib, osimertinib, cetuximab and panitumumab, was assessed using the reporting odds ratio (ROR). Nine hundred and eighty-nine ICRSs were included. A signal of disproportionate reporting (SDR) was found for afatinib (ROR = 2.70; 95% CI [2.22–3.29]) and erlotinib (ROR = 1.73; 95% CI [1.46–2.04]) with acute kidney injury, and for afatinib (ROR = 2.41; 95% CI [1.78–3.27]), cetuximab (ROR = 1.42; 95% CI [1.14–1.78]) and erlotinib (ROR = 2.23; 95% CI [1.80–2.77]) with renal failure. The preferred term “diarrhoea” was frequently reported in the included cases. An SDR was found for erlotinib with haemolytic and uremic syndrome (ROR = 4.01; 95% CI [1.80–8.94]) and thrombotic microangiopathy (ROR = 4.94; 95% CI [2.80–8.72]). No SDR was seen for glomerular or tubule-interstitial diseases. This study showed that the anti-EGFR drug renal toxicity is mainly related to renal failure in the context of digestive toxicity.


  • Open Access

    High Incidence of Amoxicillin-Induced Crystal Nephropathy in Patients Receiving High Dose of Intravenous Amoxicillin

    by Anne-Sophie Garnier, Juliette Dellamaggiore, Benoit Brilland, Laurence Lagarce, Pierre Abgueguen, Alain Furber, Erick Legrand, Jean-François Subra, Guillaume Drablier, Jean-François Augusto

    Background: Amoxicillin (AMX)-induced crystal nephropathy (AICN) is considered as a rare complication of high dose intravenous (IV) AMX administration. However, recently, its incidence seems to be increasing based on French pharmacovigilance centers. Occurrence of AICN has been observed mainly with IV administration of AMX and mostly under doses over 8 g/day. Given that pharmacovigilance data are based on declaration, the real incidence of AICN may be underestimated. Thus, the primary objective of the present study was to determine the incidence of AICN in the current practice. Materials and Methods: We conducted a retrospective study between 1 January 2015 and 31 December 2017 in Angers University Hospital. Inclusion criteria were age over 18 years-old and IV AMX administration of at least 8 g/day for more than 24 h. Patients admitted directly into the intensive care units were excluded. Medical records of patients that developed Kidney Disease:Improving Global Outcome (KDIGO) stage 2–3 acute kidney injury (AKI) were reviewed by a nephrologist and a specialist in pharmacovigilance. AICN was retained if temporality analysis was conclusive, after exclusion of other causes of AKI, in absence of other nephrotoxic drug administration. Results: A total of 1303 patients received IV AMX for at least 24 h. Among them, 358 (27.5%) were exposed to AMX doses of at least 8 g/day and were included. Patients were predominantly males (68.2%) with a mean age of 69.1 years-old. AMX was administered for a medical reason in 78.5% of cases. Patients received a median dose of AMX of 12 g/day (152.0 mg/kg/day). Seventy-three patients (20.4%) developed AKI, 42 (56.8%) of which were KDIGO stage 2 or 3. Among the latter, AICN diagnosis was retained in 16 (38.1%) patients, representing an incidence of 4.47% of total patients exposed to high IV AMX doses. Only female gender was associated with an increased risk of AICN. AMX dose was not significantly associated with AICN development. Conclusion: This study suggests a high incidence of AICN in patients receiving high IV AMX doses, representing one third of AKI causes in our study. Female gender appeared as the sole risk factor for AICN in this study.


  • Liver sinusoidal obstruction syndrome associated with trastuzumab emtansine treatment for breast cancer

    by Nina Duret-Aupy, Laurence Lagarce, Anaise Blouet, Sami Kettani, Cécile Conte, Delphine Bourneau-Martin, Guillaume Drablier, Amine Umlil, Marie Briet


  • Risperidone and Intracranial Hypertension: A Case Report and Literature Review

    by Elise Riquin, Laurine Egreteau, Lucie Salmon, Léna Le Verger, Laurence Lagarce


  • Méthotrexate pour grossesse extra-utérine : quels risques en cas de nouvelle grossesse ?

    by Laurence Lagarce, Nathalie Bernard, Patrick Carlier, Silviana Phelipot-Lates, Marie-Christine Perault-Pochat, Guillaume Drablier, Delphine Bourneau-Martin, Pascale Lainé-Cessac


  • A non-pharmaceutical form ofArtemisia annuais not effective in preventingPlasmodium falciparummalaria

    by Laurence Lagarce, Nicolas Lerolle, Pierre Asfar, Yohann Le Govic, Pascale Lainé-Cessac, Ludovic de Gentile

    Non-pharmaceutical forms of Artemisia annua ( a Chinese plant containing artemisinin) are used by some travellers who believe these products are safer than anti-malarial drugs. We report two cases of severe Plasmodium falciparum malaria requiring hospitalization in an Intensive Care Unit following prophylaxis with non-pharmaceutical A. annua in French travellers.


  • États des lieux et expertise de l’usage hors AMM du méthotrexate en gynécologie–obstétrique : travail du CNGOF

    by H. Marret, A. Fauconnier, G. Dubernard, H. Misme, L. Lagarce, M. Lesavre, H. Fernandez, C. Mimoun, C. Tourette, S. Curinier, et al.